These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 10375388

  • 1. Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
    Kereiakes DJ, Mueller M, Howard W, Lacock P, Anderson LC, Broderick TM, Roth EM, Whang DD, Abbottsmith CW.
    J Thromb Thrombolysis; 1999 Jun; 7(3):265-76. PubMed ID: 10375388
    [Abstract] [Full Text] [Related]

  • 2. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
    Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS.
    Circulation; 1999 Feb 09; 99(5):620-5. PubMed ID: 9950658
    [Abstract] [Full Text] [Related]

  • 3. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
    Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC.
    Am Heart J; 2002 Apr 09; 143(4):602-11. PubMed ID: 11923796
    [Abstract] [Full Text] [Related]

  • 4. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb 09; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 5. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 6. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM.
    JAMA; 1997 Aug 13; 278(6):479-84. PubMed ID: 9256222
    [Abstract] [Full Text] [Related]

  • 7. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.
    Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tcheng JE.
    Am Heart J; 2002 Jul 13; 144(1):151-8. PubMed ID: 12094202
    [Abstract] [Full Text] [Related]

  • 8. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Lösche W, Breddin HK.
    Thromb Res; 2001 Apr 01; 102(1):39-48. PubMed ID: 11323013
    [Abstract] [Full Text] [Related]

  • 9. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
    Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ.
    J Am Coll Cardiol; 1997 Jul 01; 30(1):149-56. PubMed ID: 9207636
    [Abstract] [Full Text] [Related]

  • 10. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
    Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ.
    Clin Appl Thromb Hemost; 1999 Apr 01; 5(2):122-30. PubMed ID: 10725993
    [Abstract] [Full Text] [Related]

  • 11. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.
    Thromb Res; 2013 Jul 01; 132(1):e36-41. PubMed ID: 23791395
    [Abstract] [Full Text] [Related]

  • 12. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
    Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, Glazer S, Tcheng JE.
    Am Heart J; 2001 Feb 01; 141(2):226-33. PubMed ID: 11174336
    [Abstract] [Full Text] [Related]

  • 13. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kübler W, Bode C.
    Circulation; 2000 Sep 26; 102(13):1490-6. PubMed ID: 11004138
    [Abstract] [Full Text] [Related]

  • 14. Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
    Mukherjee D, Chew DP, Robbins M, Yadav JS, Raymond RE, Moliterno DJ.
    J Thromb Thrombolysis; 2001 Apr 26; 11(2):151-4. PubMed ID: 11406730
    [Abstract] [Full Text] [Related]

  • 15. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.
    Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA.
    Am Heart J; 1999 Jul 26; 138(1 Pt 1):49-54. PubMed ID: 10385763
    [Abstract] [Full Text] [Related]

  • 16. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 17. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ, Broderick TM, Roth EM, Whang D, Shimshak T, Runyon JP, Hattemer C, Schneider J, Lacock P, Mueller M, Abbottsmith CW.
    Am J Cardiol; 1999 Aug 15; 84(4):391-5. PubMed ID: 10468074
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.